PL408347A1 - Kombinacja, zastosowanie kombinacji oraz zastosowanie agonisty receptora S1P - Google Patents

Kombinacja, zastosowanie kombinacji oraz zastosowanie agonisty receptora S1P

Info

Publication number
PL408347A1
PL408347A1 PL408347A PL40834703A PL408347A1 PL 408347 A1 PL408347 A1 PL 408347A1 PL 408347 A PL408347 A PL 408347A PL 40834703 A PL40834703 A PL 40834703A PL 408347 A1 PL408347 A1 PL 408347A1
Authority
PL
Poland
Prior art keywords
inhibitors
combination
antagonists
expression
receptor agonist
Prior art date
Application number
PL408347A
Other languages
English (en)
Inventor
Carolyn Ann Foster
Peter C. Hiestand
Paul William Glue
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL408347A1 publication Critical patent/PL408347A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Wynalazek dotyczy kombinacji zawierającej pierwszy składnik czynny wybrany spośród 2-amino-2-[2-(4-oktylofenylo)etylo]propano-1,3-diol, w postaci wolnej albo w postaci farmaceutycznie dopuszczalnej soli oraz fosforanu-FTY720, oraz składnik towarzyszący wybrany z grupy składającej się z interferonów, zmodyfikowanych ligandów peptydowych, immunosupresantów, inhibitorów deaminazy adenozynowej, inhibitorów mTOR, immunoglobuliny G IV, przeciwciał monoklonalnych przeciwko znacznikom powierzchniowym limfocytów T, cytokin promujących TH2, związków, które hamują ekspresję cytokin promujących TH1, środków przeciwspastycznych, antagonistów receptora glutaminianowego AMPA, inhibitorów katepsyny S, inhibitorów ekspresji VCAM-1 lub antagonistów jego ligandu oraz przeciwciał przeciwko czynnikowi hamującemu migrację makrofagów oraz zastosowania takiej kombinacji. Wynalazek dotyczy również zastosowania agonisty receptora S1P.
PL408347A 2002-09-24 2003-09-23 Kombinacja, zastosowanie kombinacji oraz zastosowanie agonisty receptora S1P PL408347A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41317202P 2002-09-24 2002-09-24
US48513203P 2003-07-07 2003-07-07

Publications (1)

Publication Number Publication Date
PL408347A1 true PL408347A1 (pl) 2014-08-18

Family

ID=32045240

Family Applications (2)

Application Number Title Priority Date Filing Date
PL03375053A PL375053A1 (pl) 2002-09-24 2003-09-23 Agoniści receptora sfingozyno-1-fosforanu w leczeniu zaburzeń demielinizacyjnych
PL408347A PL408347A1 (pl) 2002-09-24 2003-09-23 Kombinacja, zastosowanie kombinacji oraz zastosowanie agonisty receptora S1P

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL03375053A PL375053A1 (pl) 2002-09-24 2003-09-23 Agoniści receptora sfingozyno-1-fosforanu w leczeniu zaburzeń demielinizacyjnych

Country Status (16)

Country Link
US (4) US20060046979A1 (pl)
EP (3) EP2251007A3 (pl)
JP (2) JP4509028B2 (pl)
KR (4) KR101095807B1 (pl)
CN (3) CN1708293A (pl)
AU (3) AU2003266404B2 (pl)
BR (1) BR0314760A (pl)
CA (1) CA2499622C (pl)
MX (1) MXPA05003254A (pl)
NO (2) NO334908B1 (pl)
NZ (2) NZ564626A (pl)
PL (2) PL375053A1 (pl)
RU (3) RU2478378C2 (pl)
TW (2) TWI335311B (pl)
WO (1) WO2004028521A2 (pl)
ZA (1) ZA200502032B (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010688A1 (it) 2001-11-21 2003-05-21 Univ Roma Composti immunoregolatori.
CA2473461C (en) 2002-01-11 2011-11-01 Sankyo Company, Limited Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
US20040014662A1 (en) 2002-05-08 2004-01-22 Per Lindquist Modulation of neural stem cells and neural progenitor cells
AU2003259296A1 (en) 2002-07-30 2004-02-16 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
US20050090520A1 (en) * 2003-09-12 2005-04-28 Per Lindquist Treatment of disease or injury of the nervous system with FTY720
US7638637B2 (en) 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
JP2007513972A (ja) * 2003-12-11 2007-05-31 アクシス・ファーマシューティカルズ・インコーポレイテッド 低分子治療剤または生物製剤の投与によって引き起こされる免疫応答を治療するためのカテプシンｓインヒビターの使用
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
BRPI0507944A (pt) 2004-02-24 2007-07-24 Sankyo Co composição farmacêutica
MXPA06012663A (es) * 2004-05-03 2007-01-16 Novartis Ag Combinaciones que comprenden un agonista del receptor s1p y un inhibidor de quinasa jak3.
SI1772145T1 (sl) 2004-07-16 2011-06-30 Kyorin Seiyaku Kk Postopek za učinkovito uporabo zdravila in postopek za preprečevanje stranskih učinkov
US7795472B2 (en) * 2004-10-12 2010-09-14 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride and hydrates thereof, and intermediates in the production thereof
ATE397582T1 (de) * 2004-10-22 2008-06-15 Bioprojet Soc Civ Neue dicarbonsäurederivate
KR20070085465A (ko) * 2004-11-29 2007-08-27 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
JP2008522977A (ja) 2004-12-06 2008-07-03 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−リン酸のアリールアミドアナログ
MX2007007599A (es) 2004-12-21 2007-12-07 Serono Lab Dervivados ciclicos de sulfonilamino y uso de los mismos.
UA86862C2 (en) 2005-01-31 2009-05-25 Лаборатуар Сероно С.А. N-hydroxyamide derivatives and use thereof
MX2007009848A (es) 2005-02-14 2008-03-10 Univ Virginia Agonistas de esfingosina 1-fosfato comprendiendo cicloalcanos y heterociclos de 5 miembros substituidos por grupos amino y fenilo.
GB0513431D0 (en) 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
US8178083B2 (en) * 2005-09-01 2012-05-15 Ares Trading, S.A. Treatment of optic neuritis
BRPI0615906A2 (pt) * 2005-09-09 2011-05-31 Novartis Ag tratamento de doenças autoimunes
BRPI0617077A2 (pt) * 2005-10-07 2015-01-06 Kyorin Seiyaku Kk Agente terapêutico para tratamento de doenças do fígado contendo 2-amina-1, 3-propanediol derivativo como ingrediente ativo, e método para tratamento de doenças do fígado
CN101365432B (zh) 2005-12-16 2011-06-22 默沙东公司 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物
KR20080086546A (ko) 2006-01-27 2008-09-25 유니버시티 오브 버지니아 페이턴트 파운데이션 신경병증성 통증의 치료 방법
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
JP2009526073A (ja) 2006-02-09 2009-07-16 ユニバーシティ オブ バージニア パテント ファンデーション 二環式スフィンゴシン−１−リン酸受容体アナログ
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
WO2008018427A1 (fr) * 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Dérivé d'ester de l'acide aminophosphorique et modulateur du récepteur s1p contenant ledit dérivé en tant que principe actif
KR20090041424A (ko) * 2006-08-08 2009-04-28 교린 세이야꾸 가부시키 가이샤 아미노알코올 유도체 및 그것들을 유효성분으로 하는 면역 억제제
AU2012216651B2 (en) * 2006-08-17 2013-08-01 University Of Chicago Treatment of inflammatory diseases
PL2056807T3 (pl) * 2006-08-17 2013-02-28 Univ Chicago Leczenie chorób zakaźnych
EP2097397A1 (en) 2006-11-21 2009-09-09 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
WO2008064337A2 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
AU2007323540A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
ES2617628T5 (es) 2008-03-17 2020-06-01 Actelion Pharmaceuticals Ltd Régimen de dosificación para un agonista selectivo del receptor de S1P1
MX2010012676A (es) * 2008-05-20 2011-05-10 Kyorin Seiyaku Kk Agente para mantenimiento de remision inducida.
EP3545953A1 (en) * 2008-06-20 2019-10-02 Novartis AG Paediatric compositions for treating1 multiple sclerosis
AU2009284224B2 (en) * 2008-08-18 2013-02-28 Novartis Ag Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
CN101973898B (zh) * 2010-09-09 2013-06-19 南京明生医药技术有限公司 2-对辛基苯乙基-2-氨基丙二醇衍生物及其应用
KR101820330B1 (ko) 2013-10-11 2018-01-19 테이코쿠 팔마 유에스에이, 인코포레이티드 국소 스핑고신-1-포스페이트 수용체 효현제 제형 및 이의 사용 방법
CN103992985A (zh) * 2014-05-09 2014-08-20 上海大学 神经鞘氨醇在中枢神经系统中的作用
ES2769902B2 (es) * 2018-12-28 2020-12-04 Consejo Superior Investigacion Uso de secoiridoides para el tratamiento de la neuritis óptica.

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654333A (en) * 1986-02-18 1987-03-31 Unimed, Inc. Treatment of multiple sclerosis
US5138051A (en) * 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
DK0627406T3 (da) * 1992-10-21 1999-07-12 Taito Co 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler
SG64372A1 (en) 1993-12-17 1999-04-27 Novartis Ag Rapamycin derivatives
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
ES2171191T3 (es) 1994-08-22 2002-09-01 Mitsubishi Pharma Corp Compuesto de benceno y uso medicinal del mismo.
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
WO1996041807A1 (en) 1995-06-09 1996-12-27 Novartis Ag Rapamycin derivatives
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
PT1002792E (pt) * 1997-04-04 2004-12-31 Mitsubishi Pharma Corp Compostos de 2-aminopropano-1,3-diol, sua utilizacao medicinal e intermediariosda sintese dos mesmos
DE19739693A1 (de) * 1997-09-04 1999-03-11 Schering Ag Pharmazeutische Präparate zur Behandlung der Multiplen Sklerose
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
GB9903861D0 (en) 1999-02-20 1999-04-14 Zeneca Ltd Chemical compounds
JP2002537294A (ja) 1999-02-20 2002-11-05 アストラゼネカ アクチボラグ カテプシンｌ及びカテプシンｓの阻害剤としてのジ−及びトリペプチドニトリル誘導体
WO2000049007A1 (en) 1999-02-20 2000-08-24 Astrazeneca Ab Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s
WO2000051998A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
GB9907683D0 (en) 1999-04-06 1999-05-26 Synphar Lab Inc Substituted azetidin-2-ones as cysteine protease inhibitors
GB9911417D0 (en) 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
GB9917909D0 (en) 1999-07-31 1999-09-29 Synphar Lab Inc Cysteine protease inhibitors
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
MXPA02002873A (es) 1999-09-16 2002-08-30 Axys Pharm Inc Compuestos y composiciones farmaceuticas como inhibidores de la catepsina s.
CO5280088A1 (es) 2000-04-18 2003-05-30 Smithkline Beecham Corp Inhibidores de proteasa
AU6950301A (en) * 2000-07-13 2002-01-30 Sankyo Co Amino alcohol derivatives
JP2002289768A (ja) * 2000-07-17 2002-10-04 Rohm Co Ltd 半導体装置およびその製法
ES2261463T3 (es) 2000-08-14 2006-11-16 Ortho-Mcneil Pharmaceutical, Inc. Pirazoles sustituidos.
EP1309591B1 (en) 2000-08-14 2007-01-24 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
ATE324372T1 (de) 2000-08-14 2006-05-15 Ortho Mcneil Pharm Inc Substituierte pyrazole
CA2421893A1 (en) 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
US20040024000A1 (en) 2000-10-19 2004-02-05 Rajeshwar Singh Dihydropyrimidine derivatives as cysteine protease inhibitors
US7064123B1 (en) 2000-12-22 2006-06-20 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
AU2002254174A1 (en) * 2001-03-13 2002-09-24 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
US7326801B2 (en) 2001-03-26 2008-02-05 Novartis Ag 2-amino-propanol derivatives
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
US6900237B2 (en) 2001-09-14 2005-05-31 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
RS19504A (en) 2001-09-14 2007-02-05 Aventis Pharmaceuticals Inc., Novel compounds and compositions as cathepsin inhibitors
US6963012B2 (en) 2001-09-27 2005-11-08 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
US6960692B2 (en) 2001-09-27 2005-11-01 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
EP1434769A2 (en) 2001-10-02 2004-07-07 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cysteine proteases
WO2003037892A1 (en) 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
EP1446115B1 (en) 2001-11-13 2008-02-27 Merck Frosst Canada Ltd. Cyanoalkylamino derivatives as protease inhibitors
HUP0401906A3 (en) 2001-11-14 2008-07-28 Aventis Pharma Inc Novel cathepsin s inhibitors, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
TW201100359A (en) 2011-01-01
KR101188943B1 (ko) 2012-10-08
PL375053A1 (pl) 2005-11-14
KR101095807B1 (ko) 2011-12-21
EP2251007A3 (en) 2011-03-23
NO20051934L (no) 2005-04-20
NO20131569L (no) 2005-04-20
TWI376363B (en) 2012-11-11
US20140271541A1 (en) 2014-09-18
TWI335311B (en) 2011-01-01
EP2255798B1 (en) 2014-12-24
EP2251007A2 (en) 2010-11-17
US20090324542A1 (en) 2009-12-31
EP2255798A2 (en) 2010-12-01
CN1708293A (zh) 2005-12-14
US20120225031A1 (en) 2012-09-06
EP1575576A2 (en) 2005-09-21
JP2010120962A (ja) 2010-06-03
JP4509028B2 (ja) 2010-07-21
JP2006503924A (ja) 2006-02-02
AU2010246492A1 (en) 2010-12-23
NZ564626A (en) 2009-08-28
RU2478378C2 (ru) 2013-04-10
KR20090125226A (ko) 2009-12-03
NZ538961A (en) 2008-02-29
ZA200502032B (en) 2005-10-26
MXPA05003254A (es) 2005-06-08
AU2003266404B2 (en) 2007-08-09
RU2005112714A (ru) 2006-01-27
CN102526079B (zh) 2014-06-18
BR0314760A (pt) 2005-07-26
RU2009136626A (ru) 2011-04-10
RU2391094C2 (ru) 2010-06-10
AU2007231645B2 (en) 2010-12-16
KR20050054958A (ko) 2005-06-10
WO2004028521A2 (en) 2004-04-08
CN102526079A (zh) 2012-07-04
EP2255798A3 (en) 2011-03-23
WO2004028521A3 (en) 2004-05-27
TW200406369A (en) 2004-05-01
AU2003266404A1 (en) 2004-04-19
CA2499622A1 (en) 2004-04-08
AU2007231645A1 (en) 2007-11-15
KR20080103117A (ko) 2008-11-26
RU2012153692A (ru) 2014-06-20
CA2499622C (en) 2012-01-03
US20060046979A1 (en) 2006-03-02
NO334908B1 (no) 2014-07-07
CN101843897B (zh) 2014-04-30
AU2010246492B2 (en) 2012-08-30
KR20110038188A (ko) 2011-04-13
CN101843897A (zh) 2010-09-29

Similar Documents

Publication Publication Date Title
PL408347A1 (pl) Kombinacja, zastosowanie kombinacji oraz zastosowanie agonisty receptora S1P
CY1121338T1 (el) Χρηση αλατων του αναστολεα kinασης janus (r)-3-(4-(7h-πυρρολο[2,3-d]πυριμιδιν-4-υλο)-1η-πυραζολ-1-υλο)-3-κυκλοπεντυλο- προπανονιτριλιο
DK1108435T3 (da) Forebyggende midler eller midler mod pancreatitis indeholdende anti-IL-6-receptor-antistoffer som den aktive bestanddel
DK1666481T3 (da) 3-((3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidinyl)-3-oxo-propionitril som proteinkinase inhibitor
EE200000499A (et) Angiotensiin II antagonistliku toimega toimeainetprolongeeritult vabastav preparaat, selle valmistamise meetod ja kasutamine
PT97615A (pt) Metodo para atingir um efeito terapeutico sinergistico com composicoes terapeuticas contendo pelo menos dois agentes terapeuticos seleccionados a partir de um inibidor de renina, um inibidor de enzima de conversao de angiotensina i e um antagonista de angiotensina ii
MA27230A1 (fr) Derives d'aminoindazoles comme inhibiteurs de proteines-kinase
NO20060667L (no) Ikke beroligende alfa-2-agonister 1-(2,3-dimetyl- fenyl)-etyl-1,3-dihydro-imidazol-2-tion
CA2209124A1 (en) Antitumor agent effect enhancer containing il-6 antagonist
ME00191B (me) Farmaceutske kompozicije koje obuhvataju inhibitor hmg reduktaze
HRP20120440T1 (hr) Inhibitori virusa hepatitisa c
BR0206492A (pt) Composição farmacêutica para inibir a replicação de um vìrus dentro de células, uso de pelo menos um agonista receptor de adenosina a3, e, métodos para inibir a replicação de um vìrus em células
ATE399847T1 (de) Reinigungsmittel vom typ der multiplen emulsion
MX340217B (es) Metodo para el tratamietno y bioensayo que involucra el factor de inhibicion de migracion de macrofagos (mif), como un factor de depresion del miocardio, derivado del corazon.
BR9710704A (pt) Uso de inibidores de proteina cinase c para aumentar a efic cia cl¡nica de agentes oncol¡ticos e terapia de radia-Æo
DE60302157D1 (de) Opioidrezeptorantagonisten
HUP9901794A2 (hu) Protonpumpa inhibitorok új beadási formája
HUP0303514A2 (hu) AlfavBéta6 integrin inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE445396T1 (de) 3-arylthioindol-2-carbonsäureamidderivate und ihre analoge als hemmer von caseinkinase i
EA200600675A1 (ru) Гранулы, содержащие гидрохлорид венлафаксина
MEP19108A (en) Aminoquinoline derivatives and their use as adenosine a3 ligands
BR112021020369A2 (pt) Composições e métodos de uso do seneca valley vírus (svv) para tratamento do câncer
TR199903069T2 (xx) Etkin madde olarak bir ace inhibit�r� i�eren kontroll�-sal�m farmas�tik preparat�.
EA200401137A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
YU48378B (sh) Herbicidna kompozicija